ABSTRACT
In view of new information, we are revising the way we think about and treat diabetes mellitus. In this new view, the insulin-producing beta cells are key, and preserving beta-cell function is paramount. These insights, together with recent outcome studies provide compelling arguments regarding treatments of choice.
Footnotes
Dr. Miller has disclosed speaking for Novo Nordisk, Astra Zeneca, Eli Lilly, and Janssen.
Dr. Schwartz has disclosed board membership for Arkay; teaching and speaking for Boehringer Ingelheim; and membership on advisory committee or review panels and teaching and speaking for Janssen and Salix.
- Copyright © 2019 The Cleveland Clinic Foundation. All Rights Reserved.
- Stanley S. Schwartz, MD⇑
- Main Line Health System/Lankenau Medical Center, Wynnewood, PA
- University of Pennsylvania, Philadelphia, PA
- ADDRESS:
Stanley S. Schwartz, MD, Main Line Health System/Lankenau Medical Center, 100 East Lancaster Avenue, Wynnewood, PA 19096; stschwar{at}gmail.com
ABSTRACT
In view of new information, we are revising the way we think about and treat diabetes mellitus. In this new view, the insulin-producing beta cells are key, and preserving beta-cell function is paramount. These insights, together with recent outcome studies provide compelling arguments regarding treatments of choice.
Footnotes
Dr. Miller has disclosed speaking for Novo Nordisk, Astra Zeneca, Eli Lilly, and Janssen.
Dr. Schwartz has disclosed board membership for Arkay; teaching and speaking for Boehringer Ingelheim; and membership on advisory committee or review panels and teaching and speaking for Janssen and Salix.
- Copyright © 2019 The Cleveland Clinic Foundation. All Rights Reserved.